Jazz Pharmaceuticals Q4 Earnings Outlook

On Tuesday, Jazz Pharmaceuticals JAZZ will release its latest earnings report. Here is Benzinga's outlook for the company.

Earnings and Revenue

Wall Street expects EPS of $3.00 and sales around $440.5 million.

In the same quarter last year, Jazz Pharmaceuticals posted EPS of $2.71 on sales of $396.6 million. If the company were to report inline earnings when it publishes results Tuesday, earnings would be up 10.7 percent. Revenue would be up 11.07 percent from the same quarter last year.

The company's reported EPS has stacked up against analyst estimates in the past like this:

Stock Performance

Over the last 52-week period, shares are up 8.91 percent. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.

Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. The average rating by analysts on Jazz Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Jazz Pharmaceuticals' Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.